LABT
LABT
Lakewood-Amedex Biotherapeutics Inc. Common StockIncome Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $886.75K | $-923.29K | 0% | $-2 | $-886.19K |
What's going well?
The company is investing in research and development ($182,147), which could lead to future products or breakthroughs. No major one-time charges distorted the results.
What's concerning?
LABT has no revenue, high operating expenses, and posted a large loss. Overhead costs are very high for a business with no sales, and continued losses could threaten its future.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $11.71K | $196.34K | $3.04M | $-2.84M |
What's financially strong about this company?
There is no goodwill or intangible asset risk, and the company is not reliant on inventory. Asset quality is mostly tangible.
What are the financial risks or weaknesses?
The company has almost no cash, huge short-term debt, negative equity, and more liabilities than assets. It faces severe liquidity and solvency risks.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-923.29K | $-349.69K | $0 | $125K | $-224.69K | $-349.69K |
What's strong about this company's cash flow?
The company managed to raise new debt to keep operating and benefited from a one-time boost by delaying payments to suppliers. Non-cash expenses like stock compensation and depreciation reduce the reported loss.
What are the cash flow concerns?
Cash burn is severe, with negative operating cash flow and almost no cash left. The business is highly dependent on outside funding and can't sustain itself without more debt or investment.
About Lakewood-Amedex Biotherapeutics Inc. Common Stock
http://www.lakewoodamedex.comThis biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C. Established by Roderic Dale on July 11, 2006, the firm maintains its principal office in Bradenton, Florida.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $886.75K | $-923.29K | 0% | $-2 | $-886.19K |
What's going well?
The company is investing in research and development ($182,147), which could lead to future products or breakthroughs. No major one-time charges distorted the results.
What's concerning?
LABT has no revenue, high operating expenses, and posted a large loss. Overhead costs are very high for a business with no sales, and continued losses could threaten its future.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $11.71K | $196.34K | $3.04M | $-2.84M |
What's financially strong about this company?
There is no goodwill or intangible asset risk, and the company is not reliant on inventory. Asset quality is mostly tangible.
What are the financial risks or weaknesses?
The company has almost no cash, huge short-term debt, negative equity, and more liabilities than assets. It faces severe liquidity and solvency risks.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-923.29K | $-349.69K | $0 | $125K | $-224.69K | $-349.69K |
What's strong about this company's cash flow?
The company managed to raise new debt to keep operating and benefited from a one-time boost by delaying payments to suppliers. Non-cash expenses like stock compensation and depreciation reduce the reported loss.
What are the cash flow concerns?
Cash burn is severe, with negative operating cash flow and almost no cash left. The business is highly dependent on outside funding and can't sustain itself without more debt or investment.
CEO
Kelvin Cooper
Compensation Summary
(Year )
Upcoming Earnings
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2026-06-22 | Reverse | 1:10 |
Ratings Snapshot
Rating : C